The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults

Value in Health

Volumn 14, Issue 4, 2011, Pages 513-520

  Patrick, Amanda R ^a   Shrank, William H ^a   Glynn, Robert J ^a   Solomon, Daniel H ^a   Dormuth, Colin R ^b   Avorn, Jerry ^a   Cadarette, Suzanne M ^a   Mogun, Helen ^a   Brookhart, M Alan ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bias; Confounding factors; Epidemiologic methods; Health behavior; Pharmacoepidemiology

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COMORBIDITY; CONFOUNDING VARIABLE; DEMOGRAPHY; FEMALE; HEALTH BEHAVIOR; HEALTH PROMOTION; HEALTH SERVICE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

EID: 79960028739     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.10.033     Document Type: Article

References (31)

1. Petitti DB. Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies? Ann Epidemiol 1994;4:115-8. (Pubitemid 24126302)
2. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72. (Pubitemid 28279924)
3. Rossouw JE. Debate: the potential role of estrogen in the prevention of heart disease in women after menopause. Curr Control Trials Cardiovasc Med 2000;1:135-8. (Pubitemid 32219899)
4. Garbe E, Suissa S. Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies. Hum Reprod 2004;19:8-13. (Pubitemid 38072000)
5. White HD. Adherence and outcomes: it's more than taking the pills. Lancet 2005;366:1989-91. (Pubitemid 41773370)
6. Simpson SH, Eurich, DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:15.
7. Glynn RJ, Knight EL, Levin R,et al. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 2001;12:682-9. (Pubitemid 33134531)
8. Glynn RJ, Schneeweiss S, Wang PS, et al. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol 2006;59:819-28. (Pubitemid 44040877)
9. Haley RW, Dietschy JM. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? Arch Neurol 2000;57: 1410-2.
10. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84.
11. Ray WA, Daugherty JR, Griffin MR. Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 2002;8:276-9.
12. Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006;333:999.
13. Chewning B. The healthy adherer and the placebo effect. BMJ 2006; 333:18-9.
14. Avorn J. Review: good adherence (compared with poor adherence) to drug therapy is associated with a reduction in mortality. ACP J Club 2006;145:80.
15. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipidlowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007;166:348-54. (Pubitemid 47216808)
16. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009; 119:2051-7.
17. Mantel-Teeuwisse AK, Klungel OH, Egberts TC, et al. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin. Drug Saf 2004;27:63-70. (Pubitemid 38186938)
18. Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. (Pubitemid 17055592)
19. Toh S, Hernandez-Diaz S. Statins and fracture risk. A systematic review. Pharmacoepidemiol Drug Saf 2007;16:627-40. (Pubitemid 47039529)
20. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7. (Pubitemid 351160875)
21. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999;10:37-48. (Pubitemid 29014427)
22. Greenland S. Quantifying biases in causal models: classical confounding vs collider-stratification bias. Epidemiology 2003;14:300-6. (Pubitemid 40417081)
23. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004;15:615-25. (Pubitemid 40416916)
24. Jackson LA, Nelson JC, Benson P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol 2006;35:345-52.
25. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41. (Pubitemid 41713745)
26. Brookhart MA, et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006;17:268-75.
27. Setoguchi S, et al. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc 2008; 56:1644-50.
28. Cadarette SM, et al. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 2008;148:637-46. (Pubitemid 351669108)
29. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007;176:627-32. (Pubitemid 46426056)
30. Schneeweiss S, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007;45(10 Suppl. 2):S131-42.
31. Solomon DH, Avorn J, Sturmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006; 54:1378-89.